2-chloro-5-nitrobenzanilide

01/01/2020 - "We previously showed that pharmacologic inhibition of PPARγ by GW9662 boosts αPD-L1 and αPD-1 antibody efficacy in treating murine mammary tumors. "
02/08/2018 - "MATERIAL AND METHODS BGC-823 cells were cultured and divided into 5 independent groups: Tumor, HSYA, HSYA+PPARγ inhibitor (GW9662), and PPARg agonist (RGZ), RGZ+GW9662. "
12/05/2013 - "In vivo, GW9662 pre-treatment inhibits the tumor-seeding ability of BT474 cells. "
09/01/2014 - "Transient transfection of cancer cells with a dominant-negative PPARγ mutant or treatment with a PPARγ antagonist (GW9662) reversed the inhibitory effect of resveratrol. "
11/01/2013 - "In the xenograft model, GW9662 abolished the therapeutic effect of 5-ASA, which decreased tumor weight and volume by 80% in SCID mice compared with untreated mice. "

12/05/2023 - "GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPARγ/CD36 pathway and altering the gut microbiota."
01/01/2022 - "In summary, our data suggest that the PPARγ antagonist GW9662 attenuates the development of a diet-induced NAFLD and that this is associated with a protection against the activation of the TLR4 signaling cascade."
01/01/2022 - "Here, we determined the effects of GW9662 on the development of NAFLD and molecular mechanisms involved. "
01/25/2023 - "As expected, the anti-NAFLD effect induced by MBPH, characterized by the alleviation of hepatic vacuolar degeneration, hepatic steatosis, and fibrosis, was effectively abrogated with PPARγ inhibitor (GW9662) treatment. "
01/01/2022 - "GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease."

07/08/2011 - "Coadministration of GW9662 with telmisartan abolished the above mentioned greater protective effects of telmisartan against vascular injury than losartan in db/db mice. "
07/08/2011 - "We compared the effects of telmisartan, telmisartan combined with GW9662 (a PPARγ antagonist), and losartan with no PPARγ activity on vascular injury in obese type 2 diabetic db/db mice. "
06/15/2012 - "To test whether telmisartan ameliorates vascular injury in the chronic kidney disease model rat through the PPAR-γ pathway, telmisartan (5 mg/kg per day, orally), losartan (5 mg/kg per day, orally) or telmisartan plus PPAR-γ antagonist, GW9662 (1 mg/kg/day, i.p.), was administered for 14 days to subtotal nephrectomized rats (Nx). "

10/19/2023 - "Additionally, GW9662 treatment decreased the expression of several inflammation related genes. "
02/01/2023 - "GW9662 treatment reduced MFG-E8 expression but did not significantly affect airway inflammation. "
11/15/2021 - "In contrast, GW9662 could impede the LIPUS-mediated downregulation of RAVSMC proliferation and inflammation under AngII stimulation conditions in vivo and in vitro. "
06/15/2021 - "Furthermore, GW9662 or si-PPARγ exacerbated the inhibition of cell viability, migration, angiogenesis, and aggravated inflammation induced by PFOS in HTR-8/SVneo and JEG-3 cells. "
10/01/2018 - "Conversely, GW9662 inhibited the polarization of microglia to M2 and aggravated inflammation and axonal injury. "

12/05/2023 - "The liver pathological analysis indicated that GW9662 alleviated the hepatic steatosis and fibrosis. "
01/25/2023 - "As expected, the anti-NAFLD effect induced by MBPH, characterized by the alleviation of hepatic vacuolar degeneration, hepatic steatosis, and fibrosis, was effectively abrogated with PPARγ inhibitor (GW9662) treatment. "
09/01/2023 - "GW9662 reversed the pro-steatotic effect of adelmidrol and improved fibrosis. "
08/01/2012 - "Histopathologic analyses showed that telmisartan suppressed myocardial fibrosis compared with that of the control, whereas GW9662 negated the telmisartan effect. "
05/01/2008 - "Telmisartan effectively inhibited the vascular lesion formation such as medial thickness and perivascular fibrosis, but not telmisartan plus GW9662. "